GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

US10952980B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Daniel L. Kaufman · Santa Monica, US
• Jide Tian · Los Angeles, US

Key dates

• Filing date: Oct 4, 2019
• Grant date: Mar 23, 2021
• Expiry date: Oct 4, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P5/50
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).